Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Nov;74(9):1392–1396. doi: 10.1038/bjc.1996.554

Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals.

A Hagiwara 1, T Takahashi 1, K Sawai 1, C Sakakura 1, H Tsujimoto 1, T Imanishi 1, M Ohgaki 1, J Yamazaki 1, S Muranishi 1, A Yamamoto 1, T Fujita 1
PMCID: PMC2074786  PMID: 8912534

Abstract

A new delivery formulation (5FU-MS) of 5-fluorouracil (5FU), 5FU incorporated in microspheres composed of poly(glycolide-co-lactide) matrix, has been developed for the treatment of peritoneal carcinomatosis, and is designed to slowly release the incorporated 5FU for 3 weeks. Intraperitoneal 5FU-MS distributed higher concentrations of 5FU to the intraperitoneal tissues, such as the omentum and the mesentery, for a longer period with lower blood plasma concentrations than did the aqueous 5FU solution in rats. In experiments using mice, the lethal toxicity, determined by the probit method, in 5FU-MS was reduced to less than half that in aqueous 5FU solution. We evaluated the therapeutic effects on peritoneal carcinomatosis induced by the intraperitoneal inoculation of B-16 PC melanoma cells. The therapeutic effects of 5FU-MS were enhanced when compared with both the equivalent doses and same toxicity doses of the aqueous 5FU solution.

Full text

PDF
1394

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gyves J. W., Ensminger W. D., Stetson P., Niederhuber J. E., Meyer M., Walker S., Janis M. A., Gilbertson S. Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system. Clin Pharmacol Ther. 1984 Jan;35(1):83–89. doi: 10.1038/clpt.1984.12. [DOI] [PubMed] [Google Scholar]
  2. Hagiwara A., Takahashi T., Kojima O., Sawai K., Yamaguchi T., Yamane T., Taniguchi H., Kitamura K., Noguchi A., Seiki K. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet. 1992 Mar 14;339(8794):629–631. doi: 10.1016/0140-6736(92)90792-2. [DOI] [PubMed] [Google Scholar]
  3. Hagiwara A., Takahashi T., Kojima O., Yamaguchi T., Sasabe T., Lee M., Sakakura C., Shoubayashi S., Ikada Y., Hyon S. H. Pharmacologic effects of cisplatin microspheres on peritoneal carcinomatosis in rodents. Cancer. 1993 Feb 1;71(3):844–850. doi: 10.1002/1097-0142(19930201)71:3<844::aid-cncr2820710330>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  4. Hagiwara A., Takahashi T., Sawai K., Taniguchi H., Shimotsuma M., Okano S., Sakakura C., Tsujimoto H., Osaki K., Sasaki S. Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res. 1993 Feb 1;53(3):687–692. [PubMed] [Google Scholar]
  5. Hagiwara A., Takahashi T., Ueda T., Lee R., Takeda M., Itoh T. Intraoperative chemotherapy with carbon particles adsorbing mitomycin C for gastric cancer with peritoneal dissemination in rabbits. Surgery. 1988 Nov;104(5):874–881. [PubMed] [Google Scholar]
  6. Inaba M., Mitsuhashi J., Ozawa S. Kinetic analysis of 5-fluorouracil action against various cancer cells. Jpn J Cancer Res. 1990 Oct;81(10):1039–1044. doi: 10.1111/j.1349-7006.1990.tb03343.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jones R. A., Buckpitt A. R., Londer H. H., Myers C. E., Chabner B. A., Boyd M. R. Potential clinical applications of a new method for quantitation of plasma levels of 5-fluorouracil and 5-fluorodeoxyuridine. Bull Cancer. 1979;66(1):75–78. [PubMed] [Google Scholar]
  8. Jones R. B., Myers C. E., Guarino A. M., Dedrick R. L., Hubbard S. M., DeVita V. T. High volume intraperitoneal chemotherapy ("belly bath") for ovarian cancer. Pharmacologic basis and early results. Cancer Chemother Pharmacol. 1978;1(3):161–166. doi: 10.1007/BF00253116. [DOI] [PubMed] [Google Scholar]
  9. Mandache E., Negoescu A., Moldoveanu E. The development of lymphatic follicles in the omentum after intraperitoneal stimulation of rats. Morphol Embryol (Bucur) 1989 Apr-Jun;35(2):139–147. [PubMed] [Google Scholar]
  10. Masuike T., Watanabe I., Takemoto Y. [Quantitative method of 5-fluorouracil and its metabolites in biological samples using high performance liquid chromatography]. Yakugaku Zasshi. 1985 Nov;105(11):1058–1064. doi: 10.1248/yakushi1947.105.11_1058. [DOI] [PubMed] [Google Scholar]
  11. Ogawa Y., Okada H., Yamamoto M., Shimamoto T. In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers. Chem Pharm Bull (Tokyo) 1988 Jul;36(7):2576–2581. doi: 10.1248/cpb.36.2576. [DOI] [PubMed] [Google Scholar]
  12. Speyer J. L., Collins J. M., Dedrick R. L., Brennan M. F., Buckpitt A. R., Londer H., DeVita V. T., Jr, Myers C. E. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980 Mar;40(3):567–572. [PubMed] [Google Scholar]
  13. Sugarbaker P. H., Gianola F. J., Speyer J. C., Wesley R., Barofsky I., Meyers C. E. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 1985 Sep;98(3):414–422. [PubMed] [Google Scholar]
  14. Tsujimoto H., Takhashi T., Hagiwara A., Shimotsuma M., Sakakura C., Osaki K., Sasaki S., Shirasu M., Sakakibara T., Ohyama T. Site-specific implantation in the milky spots of malignant cells in peritoneal dissemination: immunohistochemical observation in mice inoculated intraperitoneally with bromodeoxyuridine-labelled cells. Br J Cancer. 1995 Mar;71(3):468–472. doi: 10.1038/bjc.1995.95. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES